If you suffer from any kind of chronic pain or perhaps have endured a major surgery in recent years, you’re probably familiar with Fentanyl. It’s a powerful, fast-acting narcotic painkiller that is typically appropriate for severe, acute pain. It’s highly addictive, possessing many heroin-like qualities. It’s also extremely deadly when taken in high doses or in combination with other substances, which can cause respiratory distress.
Yet the makers of this drug have continued to advertise it as a common pain relief drug. So perhaps it shouldn’t be surprising, in light of a growing body of research to suggest marijuana could be a safer, more effective alternative to the scourge of painkiller addiction and overdoses in the U.S., that its manufacturer is pushing to quash the potential competition. It makes even more sense when you learn the company, Insys Therapeutics, recently came out with a synthetic cannabis product.
A recent investigation by The Washington Post reveals the Arizona-based company dropped a $500,000 donation to the group, “Arizonans for Responsible Drug Policy,” a group that staunchly opposes legalizing marijuana. This amounts to more than one-third of the money raised by the group. Continue reading